Expected Moves

The Read: Amphastar's stock dropped sharply twice in early 2026, first on a significant Q4 earnings miss and weak guidance highlighting margin pressure from rising costs and slowing branded product growth, then further on disappointing revenue outlook and margin concerns despite FDA approval of a new drug.